All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Treatment preferences and unmet needs of patients with psoriasis in China
|
Results of a survey of 50 dermatologists and 300 patients with moderate-to-severe psoriasis (msPsO) from five regional dermatology centers in China have been published in Dermatology and Therapy by Kuang et al.1 The survey identified unmet needs and treatment preferences for the systematic treatment of patients with msPsO.
|
| Key learnings: |
|
Both dermatologists and patients with msPsO reported a preference for once-daily oral treatments over biweekly subcutaneous injections when efficacy and safety profiles were comparable. |
|
The primary reasons for discontinuation of oral systemic treatments were unsatisfactory effectiveness and treatment toxicity, while loss of efficacy over time and injection site reactions were significant issues for biologics. |
|
The study highlighted that traditional oral treatments remain the main systemic treatments for msPsO in China owing to their lower costs, with acitretin the most commonly used. |
| These findings suggest a need for more effective, safe, and convenient treatments that can maintain long-term efficacy, addressing the current unmet needs in the management of patients with msPsO in China. |
- Kuang Y, Li Y, Lv C, et al. Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China. Dermatol Ther (Heidelb). 2024;14(5):1245-1257. DOI: 1007/s13555-024-01159-3
More about...
Your opinion matters
4 votes - 19 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox